Virchow's triad is traditionally invoked to explain pathophysiologic mechanisms leading to
thrombosis, alleging concerted roles for abnormalities in blood composition, vessel wall …

Generation of a hemostatic clot requires thrombin-mediated conversion of fibrinogen to
fibrin. Previous in vitro studies have demonstrated that the thrombin concentration present at …

Background Fitusiran, a subcutaneous investigational small interfering RNA therapeutic,
targets antithrombin to rebalance haemostasis in people with haemophilia A or haemophilia …

Background Current hemophilia treatment involves frequent intravenous infusions of clotting
factors, which is associated with variable hemostatic protection, a high treatment burden …

Hemophilia A and B are inherited bleeding disorders characterized by deficiencies in
procoagulant factor VIII (FVIII) or factor IX (FIX), respectively. There remains a substantial …

By the use of a fluorogenic thrombin substrate and continuous calibration of each individual
sample, it is now possible to obtain a thrombin generation (TG) curve (or thrombogram) in …

Hemostatic clot formation entails thrombin-mediated cleavage of fibrinogen to fibrin.
Previous in vitro studies have shown that the thrombin concentration present during clot …

ContextScreening of patients with venous thromboembolism (VTE) for thrombophilic risk
factors is common clinical practice. Because of the large number of risk factors, assessing …

Background Fitusiran, a subcutaneous investigational siRNA therapeutic, targets
antithrombin with the goal of rebalancing haemostasis in people with haemophilia A or …

Maintaining normal hemostasis relies on a regulated system of procoagulant and
anticoagulant pathways, and disruption of these processes leads to the loss of hemostatic …